2020
Exenatide extended release in patients with type 1 diabetes with and without residual insulin production
Herold KC, Reynolds J, Dziura J, Baidal D, Gaglia J, Gitelman SE, Gottlieb PA, Marks J, Philipson LH, Pop‐Busui R, Weinstock RS. Exenatide extended release in patients with type 1 diabetes with and without residual insulin production. Diabetes Obesity And Metabolism 2020, 22: 2045-2054. PMID: 32573927, PMCID: PMC8009602, DOI: 10.1111/dom.14121.Peer-Reviewed Original ResearchMeSH KeywordsDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2ExenatideGlycated HemoglobinHumansHypoglycemic AgentsInsulinVenomsConceptsExenatide extended releaseResidual insulin productionBeta-cell functionType 1 diabetesC-peptidePlacebo groupPrimary outcomeWeek 12ER groupInsulin productionDetectable C-peptide levelsResidual beta-cell functionGLP-1 receptor agonistsRandomized placebo-controlled trialExtended releaseTotal insulin doseMean HbA1c levelPlacebo-controlled trialC-peptide levelsDetectable levelsCell functionShort-term improvementHbA1c levelsStudy drugAdverse events
2018
Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis
Perdigoto AL, Preston-Hurlburt P, Clark P, Long SA, Linsley PS, Harris KM, Gitelman SE, Greenbaum CJ, Gottlieb PA, Hagopian W, Woodwyk A, Dziura J, Herold KC. Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis. Diabetologia 2018, 62: 655-664. PMID: 30569273, PMCID: PMC6402971, DOI: 10.1007/s00125-018-4786-9.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntibodies, Monoclonal, HumanizedArea Under CurveAutoimmunityC-PeptideCD3 ComplexCD8-Positive T-LymphocytesChildCytokinesDiabetes Mellitus, Type 1FemaleFollow-Up StudiesHumansHypoglycemic AgentsInsulinIslets of LangerhansMaleRandomized Controlled Trials as TopicRemission InductionTreatment OutcomeYoung AdultConceptsC-peptide responseType 1 diabetesMixed meal tolerance testDetectable C-peptideC-peptideInsulin useTolerance testT cellsControl groupNew-onset type 1 diabetesPeripheral blood mononuclear cellsConclusions/interpretationThese findingsAnti-CD3 monoclonal antibodyDaily insulin useBlood mononuclear cellsDiagnosis of diabetesSuccessful immune therapiesOriginal control groupCell death proteinAnergic CD8ResultsFifty-sixImmune therapyInterpretationThese findingsMononuclear cellsCytokine release
2012
Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial
Herold KC, Gitelman SE, Willi SM, Gottlieb PA, Waldron-Lynch F, Devine L, Sherr J, Rosenthal SM, Adi S, Jalaludin MY, Michels AW, Dziura J, Bluestone JA. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia 2012, 56: 391-400. PMID: 23086558, PMCID: PMC3537871, DOI: 10.1007/s00125-012-2753-4.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntibodies, Monoclonal, HumanizedC-PeptideDiabetes Mellitus, Type 1FemaleGlycated HemoglobinHumansInsulinMaleConceptsC-peptide responseType 1 diabetesImmune therapyHigh C-peptide responseCentral randomisation centreChronic autoimmune processPlacebo-treated participantsPlacebo-controlled trialPrimary outcome analysisC-peptide levelsCharacteristics of patientsSubgroup of patientsC-peptide productionTeplizumab groupClinical respondersAutoimmune processPrimary outcomeExogenous insulinMixed mealSubgroup analysisResultsThirty-fourInsulin secretionTreatment benefitBaseline imbalancesTeplizumab
2010
Early Pharmacokinetic and Pharmacodynamic Effects of Mixing Lispro With Glargine Insulin Results of glucose clamp studies in youth with type 1 diabetes
Cengiz E, Tamborlane WV, Martin-Fredericksen M, Dziura J, Weinzimer SA. Early Pharmacokinetic and Pharmacodynamic Effects of Mixing Lispro With Glargine Insulin Results of glucose clamp studies in youth with type 1 diabetes. Diabetes Care 2010, 33: 1009-1012. PMID: 20150302, PMCID: PMC2858163, DOI: 10.2337/dc09-2118.Peer-Reviewed Original ResearchConceptsType 1 diabetesGlucose clamp studiesGlucose excursionsClamp studiesMeal-related glucose excursionsRapid-acting insulin analoguesRapid-acting insulinEuglycemic glucose clampTime-action curvePharmacodynamic peakA1c levelsTreatment burdenPharmacodynamic effectsDaily injectionsUnits/Pharmacodynamic actionClinical studiesGlucose clampMixed injectionGlargineEarly pharmacokineticsInsulin analoguesObjective clinicianInsulin pharmacokineticsLispro
2009
Effects of coping skills training in school‐age children with type 1 diabetes
Grey M, Whittemore R, Jaser S, Ambrosino J, Lindemann E, Liberti L, Northrup V, Dziura J. Effects of coping skills training in school‐age children with type 1 diabetes. Research In Nursing & Health 2009, 32: 405-418. PMID: 19488997, PMCID: PMC2720049, DOI: 10.1002/nur.20336.Peer-Reviewed Original ResearchMedium-Chain Fatty Acids Improve Cognitive Function in Intensively Treated Type 1 Diabetic Patients and Support In Vitro Synaptic Transmission During Acute Hypoglycemia
Page KA, Williamson A, Yu N, McNay EC, Dzuira J, McCrimmon RJ, Sherwin RS. Medium-Chain Fatty Acids Improve Cognitive Function in Intensively Treated Type 1 Diabetic Patients and Support In Vitro Synaptic Transmission During Acute Hypoglycemia. Diabetes 2009, 58: 1237-1244. PMID: 19223595, PMCID: PMC2671041, DOI: 10.2337/db08-1557.Peer-Reviewed Original ResearchConceptsType 1 diabetic subjectsMedium-chain triglyceridesSynaptic transmissionDiabetic subjectsMedium-chain triglyceride ingestionType 1 diabetic patientsRat hippocampal slice preparationHippocampal synaptic transmissionBeta-hydroxybutyrate levelsType 1 diabetesHypoglycemic clamp studiesHippocampal slice preparationControl glucose concentrationsTriglyceride ingestionDiabetic patientsFatty acidsAcute hypoglycemiaSymptomatic responseHippocampal slicesSlice preparationFree fatty acidsGlucose levelsClamp studiesTherapeutic advantageNeuronal activity
2008
Effect of Age of Infusion Site and Type of Rapid-Acting Analog on Pharmacodynamic Parameters of Insulin Boluses in Youth With Type 1 Diabetes Receiving Insulin Pump Therapy
Swan KL, Dziura JD, Steil GM, Voskanyan GR, Sikes KA, Steffen AT, Martin ML, Tamborlane WV, Weinzimer SA. Effect of Age of Infusion Site and Type of Rapid-Acting Analog on Pharmacodynamic Parameters of Insulin Boluses in Youth With Type 1 Diabetes Receiving Insulin Pump Therapy. Diabetes Care 2008, 32: 240-244. PMID: 19017777, PMCID: PMC2628686, DOI: 10.2337/dc08-0595.Peer-Reviewed Original ResearchConceptsInsulin pump therapyGlucose infusion rateType 1 diabetesDay 1Day 4Pump therapyInsulin aspartPharmacodynamic parametersInsulin actionInsulin bolusRapid acting analogsEuglycemic clamp procedureExogenous glucose infusionGIR curveEffect of agePharmacodynamic measuresPharmacodynamic characteristicsClamp procedureInfusion siteGlucose infusionInfusion rateInsulin analoguesType 1AspartOverall insulin actionFully Automated Closed-Loop Insulin Delivery Versus Semiautomated Hybrid Control in Pediatric Patients With Type 1 Diabetes Using an Artificial Pancreas
Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully Automated Closed-Loop Insulin Delivery Versus Semiautomated Hybrid Control in Pediatric Patients With Type 1 Diabetes Using an Artificial Pancreas. Diabetes Care 2008, 31: 934-939. PMID: 18252903, DOI: 10.2337/dc07-1967.Peer-Reviewed Original ResearchConceptsType 1 diabetesGlucose levelsHCl groupFCL groupInsulin pumpBeta cell replacement therapyPostprandial glycemic excursionsPostprandial glucose excursionsPostprandial glucose levelsClosed-loop glucose controlArtificial pancreasClosed-loop artificial pancreasPediatric patientsPostprandial excursionsBolus dosesGlycemic excursionsReplacement therapySubcutaneous routeGlucose controlGlucose excursionsInsulin delivery systemsHybrid closed-loop controlInsulin absorptionType 1Dl
2007
Effect of Puberty on the Pharmacodynamic and Pharmacokinetic Properties of Insulin Pump Therapy in Youth With Type 1 Diabetes
Swan KL, Weinzimer SA, Dziura JD, Steil GM, Voskanyan GR, Steffen AT, Martin ML, Tamborlane WV. Effect of Puberty on the Pharmacodynamic and Pharmacokinetic Properties of Insulin Pump Therapy in Youth With Type 1 Diabetes. Diabetes Care 2007, 31: 44-46. PMID: 17909083, DOI: 10.2337/dc07-0737.Peer-Reviewed Original Research
2006
Optimal control of type 1 diabetes mellitus in youth receiving intensive treatment
Springer D, Dziura J, Tamborlane WV, Steffen AT, Ahern JH, Vincent M, Weinzimer SA. Optimal control of type 1 diabetes mellitus in youth receiving intensive treatment. The Journal Of Pediatrics 2006, 149: 227-232. PMID: 16887440, DOI: 10.1016/j.jpeds.2006.03.052.Peer-Reviewed Original ResearchConceptsType 1 diabetes mellitusRace/ethnicityLow socioeconomic statusSocioeconomic statusDiabetes mellitusLarge clinical practiceDuration of diabetesOptimal glycemic controlBody mass indexPoor metabolic controlAge 18 yearsGlycemic targetsInjection therapyGlycemic controlDiabetes controlMass indexFemale sexDatabase reviewInsulin administrationIntensive treatmentMonths durationTrial recommendationsMultiple linear regression analysisTherapeutic goalsClinical practice
2004
Persistence of Benefits of Continuous Subcutaneous Insulin Infusion in Very Young Children With Type 1 Diabetes: A Follow-up Report
Weinzimer SA, Ahern JH, Doyle EA, Vincent MR, Dziura J, Steffen AT, Tamborlane WV. Persistence of Benefits of Continuous Subcutaneous Insulin Infusion in Very Young Children With Type 1 Diabetes: A Follow-up Report. Pediatrics 2004, 114: 1601-1605. PMID: 15574621, DOI: 10.1542/peds.2004-0092.Peer-Reviewed Original ResearchMeSH KeywordsChildChild, PreschoolDiabetes Mellitus, Type 1Diabetic KetoacidosisFemaleFollow-Up StudiesGlycated HemoglobinHumansHypoglycemiaInfantInsulin Infusion SystemsConceptsContinuous subcutaneous insulin infusionType 1 diabetesMultiple daily injectionsSubcutaneous insulin infusionSevere hypoglycemiaDaily injectionsInsulin infusionRate of SHMonths of CSIIYoung childrenEpisodes of DKAOlder pediatric patientsVery Young ChildrenPersistence of benefitHypoglycemia frequencyYounger patientsGlycemic controlPediatric patientsPump treatmentClinic databaseSafety dataEmergency treatmentAge groupsType 1Diabetes
2002
Brain glucose levels are elevated in chronically hyperglycemic diabetic rats: No evidence for protective adaptation by the blood brain barrier
Jacob RJ, Fan X, Evans ML, Dziura J, Sherwin RS. Brain glucose levels are elevated in chronically hyperglycemic diabetic rats: No evidence for protective adaptation by the blood brain barrier. Metabolism 2002, 51: 1522-1524. PMID: 12489061, DOI: 10.1053/meta.2002.36347.Peer-Reviewed Original ResearchConceptsDiabetic ratsBB/Wor diabetic ratsLong-term adverse effectsHyperglycemic diabetic ratsProtective adaptationBlood-brain barrier transferPlasma glucose ratioBlood-brain barrierBeta-hydroxybutyrate levelsBrain glucose levelsECF glucoseAcute hyperglycemiaChronic hyperglycemiaBlood glucoseBrain barrierHyperglycemic groupPeripheral tissuesGlucose levelsBeta-OHBInferior colliculusECF levelsProlonged elevationHyperglycemiaFluid glucoseBrain tissue
1999
Effects of recurrent hypoglycemia on brainstem function in diabetic BB rats: protective adaptation during acute hypoglycemia.
Jacob RJ, Dziura J, Blumberg M, Morgen JP, Sherwin RS. Effects of recurrent hypoglycemia on brainstem function in diabetic BB rats: protective adaptation during acute hypoglycemia. Diabetes 1999, 48: 141-145. PMID: 9892235, DOI: 10.2337/diabetes.48.1.141.Peer-Reviewed Original ResearchConceptsAntecedent recurrent hypoglycemiaRecurrent hypoglycemiaNondiabetic ratsDM ratsInsulin therapyBB ratsDiabetic ratsPlasma glucoseDiabetic BB ratsIntensive insulin therapyRelease of catecholaminesAuditory-evoked potentialsHypoglycemia counterregulationBrainstem dysfunctionDiabetic patientsHypoglycemic stimulusChronic hyperglycemiaAcute hypoglycemiaBrainstem functionAdrenergic responseInferior colliculiHypoglycemiaRatsAdverse effectsProtective adaptation